EVOK

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

Wall Street analysts forecast EVOK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVOK is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Evoke Pharma Inc revenue for the last quarter amounts to 4.28M USD, increased 61.40 % YoY.

Evoke Pharma Inc. EPS for the last quarter amounts to -0.45 USD, decreased -52.13 % YoY.

Evoke Pharma Inc (EVOK) has 3 emplpoyees as of December 15 2025.

Today EVOK has the market capitalization of 18.86M USD.